Cardiac Cachexia and Its Impact on Survival in Heart Failure Patients
AbstractBackground. Cardiac cachexia (CC) is one of indicator of poor prognosis in heart failure. Unfortunately, its existence is often overlooked by many cardiologists, this is further complicated by small number of study concerning CC, and the controversial issues they encompasses.Methods. The aim of this study is to analyze the survival in heart failure (HF) patients with cachexia complications. A retrospective cohort study was conducted on the data from Hasan Sadikin General Hospital HF registry from March 2013 August 2014. The inclusion criteria was the data registry (registrys inclusion criterias: HF patients above 18 years of age with left ventricle ejection fraction (LVEF) below 40%, time onset of HF more than 6 months and exclusion criterias were valvular diseases as primary etiology of HF). The exclusion criteria was if the patients have other chronic disease (COPD, CKD, cancer). Cardiac cachexia was diagnosed in patients fulfilling the criteria from international cachexia consensus.Results. There were 39 patients, most of them were female (61.5%), with mean LVEF 28.5% (+6.7). Cardiac cachexia was diagnosed in 6 (15.3%) patients. At 6 months of follow-up after initial enrollment, the cumulative rate of death from cardiovascular cause was 83% among cachectic as compared 37.5% among noncachectic patients p=0.001 Adjusted HR (95%CI) = 8.05 (2.4027.04). There were no association between mortality with sex (p=0.268), etiology of HF (p=0.288), LVEF (p=0.061), comorbid condition (hypertension p=0.237, diabetes mellitus p=0.163).Conclusions. We conclude that patients with cardiac cachexia is independent predictor of death in HF and warrants a special consideration in the management of HF.
Georgiadou P, Adamopoulos S. Skeletal muscle abnormalities in chronic heart failure. Curr Heart Fail Rep. 2012 Jun;9(2):128-32. PubMed PMID: 22430147. Epub 2012/03/21. eng.
Farkas J, von Haehling S, Kalantar-Zadeh K, Morley J, Anker S, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. Journal of Cachexia, Sarcopenia and Muscle. 2013 2013/09/01;4(3):173-8. English.
von Haehling S, Doehner W, Anker SD. Nutrition,
metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovascular research. 2007 January 15, 2007;73(2):298-309.
Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. The Lancet. 1997;349(9058):1050-3.
Anker SD, Laviano A, Filippatos G, John M, Paccagnella A, Ponikowski P, et al. ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. Clin Nutr. 2009 Aug;28(4):455-60. PubMed PMID: 19515464. Epub 2009/06/12. eng.
Martins T, Vitorino R, Amado F, Duarte JA, Ferreira R. Biomarkers for cardiac cachexia: reality or utopia. Clin Chim Acta. 2014 Sep 25;436:323-8. PubMed PMID: 24978823. Epub 2014/07/01. eng.
Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003 Mar 29;361(9363):1077-83. PubMed PMID: 12672310. Epub 2003/04/04. eng.
Anker SD, Steinborn W, Strassburg S. Cardiac cachexia. Ann Med. 2004;36(7):518-29. PubMed PMID: 15513302. Epub 2004/10/30. eng.
Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90(4):464-70. PubMed PMID: PMC1768165.
Doehner W, Frenneaux M, Anker SD. Metabolic Impairment in Heart Failure: The Myocardial and Systemic Perspective. Journal of the American College of Cardiology. 2014 Sep 30;64(13):1388-400. PubMed PMID: 25257642. Epub 2014/09/27. Eng.